{"id":"W2793477810","doi":"10.1016/j.ahj.2018.01.011","title":"Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)","year":2018,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"National Heart, Lung, and Blood Institute; Pharmaceuticals Bayer; National Institutes of Health; Bayer Fund; Merck; Janssen Pharmaceuticals; Bayer; AstraZeneca","keywords":"Medicine; Rivaroxaban; Revascularization; Myocardial infarction; Clopidogrel; Aspirin; Surgery; Randomized controlled trial; Clinical endpoint; Stroke (engine); Critical limb ischemia; Coronary artery disease; Internal medicine; Cardiology; Population; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07238008,0.004684532,0.00518432,0.003053772,0.003913615,0.004394297,0.002994681,0.006150951,0.01474134],"category_scores_gemma":[0.04937801,0.00363745,0.005776441,0.00289878,0.005812909,0.002398372,0.002444095,0.006310652,0.005711017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002244901,"about_ca_system_score_gemma":0.0112503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001558134,"about_ca_topic_score_gemma":0.002406266,"domain_scores_codex":[0.9415349,0.03715733,0.007766711,0.005917669,0.004914986,0.002708376],"domain_scores_gemma":[0.9831821,0.005208331,0.002687498,0.002907051,0.003444646,0.002570329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7149125,0.02553952,0.06653345,0.008982501,0.006964383,0.00134442,0.002967761,0.002632427,0.007492553,0.05771662,0.02731,0.07760393],"study_design_scores_gemma":[0.6335506,0.1065538,0.06215698,0.004337129,0.008747775,0.001081625,0.001297265,0.00616935,0.003923079,0.03691134,0.1346038,0.0006673607],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.07566163,0.006966265,0.03145719,0.007702493,0.008223352,0.8486989,0.008679928,0.0003146631,0.01229552],"genre_scores_gemma":[0.08547974,0.001184654,0.0437403,0.005975014,0.002158317,0.8557344,0.002151462,0.00006837842,0.003507675],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.07238008,"threshold_uncertainty_score":0.382787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0359267663805228,"score_gpt":0.3056857976363951,"score_spread":0.2697590312558724,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}